Dr. Xiong Guojun
Excellent Young Scholar & Lecturer
Email: gjxiong@suda.edu.cn
Biography:
Guojun Xiong, PhD, is an Excellent Young Scholar and Lecturer at the International College of Pharmaceutical Innovation, Soochow University. He received his PhD from University College London (UCL) in 2023, where he continued his research as a postdoctoral researcher until 2026. His research interests include protein-based nanomedicines for targeted drug delivery, innovative formulations for poorly soluble anticancer drugs, and translational medicine. As independent first author, he has published five SCI-indexed papers in leading pharmaceutical journals, such as Journal of Controlled Release, Drug Delivery, and International Journal of Pharmaceutics. He has also filed one UK patent and one international PCT patent, led two translational research projects supported by UCL Business (UCLB), and contributed to two English-language academic books published by Elsevier and Springer Nature.
Research Interests:
*Nanoformulations of poorly soluble drugs, biologics, and metal-based therapeutics
*Targeted delivery systems based on protein-based nanocarriers
*Cancer stem cell-targeted therapy
*Clinical translation of anticancer nanomedicines
Publications:
[1] G. Xiong, A. Vaideanu, R.D. Mellor, C. Jiang, B. Gardner, N. Stone, A.G. Schätzlein, I.F. Uchegbu, A Renally Excretable Gold Nanoparticle Oncology Platform Enabling Effective Photothermal Therapy and Chemotherapy Combination, ACS Nano Med. (2026) acsnanomed.5c00114.
[2] G. Xiong, C. Jiang, A.G. Schätzlein, I.F. Uchegbu, The colloidal stability of albumin-based drug delivery systems has a profound effect on tumoricidal activity, Drug Delivery 33 (2026) 2614801.
[3] G. Xiong, S. Li, A.G. Schätzlein, I.F. Uchegbu, Albumin-based nanoparticles encapsulating SN-38 demonstrate superior antitumor efficacy compared to irinotecan, Drug Delivery 32 (2025) 2545519.
[4] G. Xiong, S. Li, A.G. Schätzlein, I.F. Uchegbu, Amphiphilic albumin-based nanoparticles designed for the efficient delivery of taxanes, International Journal of Pharmaceutics (2025) 125965.
[5] G. Xiong, A.G. Schätzlein, I.F. Uchegbu, Acetyl-lysine human serum albumin nanoparticles activate CD44 receptors, with preferential uptake by cancer stem cells, leading to tumor eradication, Journal of Controlled Release 382 (2025) 113632.
[6] R. Mellor, G. Xiong, A. Vaideanu, B. Gardner, N. Stone, A. Schätzlein, I. Uchegbu, Clustered, SERS-Active, Ultrasmall AuNPs for Photothermal Therapy, International Journal of Nanomedicine Volume 20 (2025) 8209–8220.
[7] G. Xiong, I.F. Uchegbu, Nanoparticles and Cancer Chemotherapy, in: I.F. Uchegbu, A.G. Schätzlein, A. Lalatsa, D.R.S. Lopez (Eds.), Fundamentals of Pharmaceutical Nanoscience, Springer Nature Switzerland, Cham, 2024: pp. 423–449.
